ACADIA Pharmaceuticals Inc (ACAD) Balance Sheet

A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America.

Total Assets Chart for ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc (ACAD) total assets for FY2025 were USD 1.6B, a 31.7% change from FY2024. ACADIA Pharmaceuticals Inc's total assets grew from USD 34.1M in 2000 to USD 1.6B in 2025 (4485.3% over 25 years). Total assets compound annual growth rate: 5-year CAGR of 14.9%, 10-year CAGR of 21.6%, 20-year CAGR of 17.5%.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Assets (US Dollars)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
$3.39B
Implied Share Price
$19.80
Enterprise Value
$3.50B
Revenue (TTM)
$1.14B
EBITDA
$98.39M
Profit Margin
33.42%
Trailing P/E
8.57
Forward P/E
25.19
Price/Book (MRQ)
3.35
Price/Sales (TTM)
3.00
EV/EBITDA
35.53
EV/Revenue
3.07
Dividend Yield
—
Book Value
$7.59
Free Cash Flow (FY2025)
$105.15M
Free Cash Flow Yield
3.10%

Snapshot as of 20th October 2026 — not point-in-time controlled, may lag the live market by a few days.